# Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)

> **NCT03434158** · PHASE2 · COMPLETED · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 16 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03434158
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-06
- **Primary completion:** 2022-05-12
- **Final completion:** 2022-05-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-11-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03434158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03434158, "Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03434158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*